Lipid Nanoparticles (LNP)
Lipid nanoparticles (LNP) provide a safe and effective way to deliver poorly soluble drugs and RNA.The COVID-19 pandemic and the resulting mRNA vaccines fueled increased interest in LNP delivery in recent years, but bringing such drugs to market presents a number of challenges.
This is a highly active area of research and development, and the clinical pipeline is full of lipid nanoparticle products that offer innovative, safe and efficient solutions that traditional drug delivery systems cannot match.
key benefits of using LNP for drug delivery
Over earlier lipid-based nucleic acid delivery methods, LNP provide a number of benefits, including:
challenges with conventional drug delivery/production methods
Conventional drug delivery/production techniques have various difficulties that may reduce the effectiveness and scalability of the procedure. Several of these challenges include:
Limited scalability
Conventional drug delivery/lipid manufacturing techniques, such as bulk homogenization and microfluidic devices, have difficulties scaling up to industrial production levels.
Low encapsulation efficiency
Using conventional techniques may lead to an LNP that contains less of the intended medication, which will have a negative impact on efficacy.
Limited ability to control particle size and distribution
The efficacy and toxicity of drugs can be affected by lipid particle size and distribution, although this ability may be constrained by current approaches.
Limited reproducibility
Due to changes in batch-to-batch production, traditional methods may have lower repeatability, which could result in variable drug distribution and efficacy.
High cost and time commitment
Due to the utilisation of pricey machinery, reagents, and labour, conventional drug delivery/production can be time and money intensive.
To overcome these obstacles, various cutting-edge techniques are being developed, such as nano-precipitation, solvent diffusion, and spray drying, to increase the effectiveness and scalability of LNP development and manufacturing.
our expertise
Our lipid chemistry team has expertise in synthesis of a variety of lipid molecules from mg to multi gram scale.
- We have expertise in synthesis of a variety of lipids such as PEGylated lipids, Phospholipids, Fluorescent lipids, lonic lipids, etc.
- Our expertise includes developing purification methods to ensure high purity lipid products.
- We characterise our final lipid compounds by various other analyses (i.e. LCMS, 1H-NMR) supplying high quality materials with COA for further research and testing.
- We customise our project management approach as per the requirements of our collaborators.
- We use high quality starting materials to avoid contamination of isomeric impurities in our final products.
- We ensure purity of intermediates and final lipid compounds with specialized analytical protocols, utilizing sensitive lipid analysis instruments such as CAD HPLC and relevant columns.
collaborators
We have an extensive track record of collaborations and have supported marquee pharma across the globe with up to 52 FTEs since 2004
Bharat Majeti
Head of LNP Technology
RVAC Medicines
We understand that lipid chemistry is complex and requires significant expertise in synthesis, purification, and analysis. Therefore, we looked for a competent and reliable CRO partner to support our requirements and found o2h Discovery. We have done several projects with o2h.
Prof Kirill Alexandrov
CSIRO-QUT Synthetic Biology Alliance
We have worked with o2h team on a range of synthetic projects and had consistently positive experience. The combination of competence, effective project management and detailed documentation made us go back again and again. The company offers excellent value for money and makes a significant effort to work within the given funding envelope.
Brian Dymock
Head of QEDDI
Our relationship with o2h over many years supporting our medicinal chemistry projects in QEDDI has been highly productive. With o2h’s help we have progressed our portfolio to an advanced stage ready for partnering. We are very pleased with the efficiency, productivity and communication with o2h chemists and look forward to further positive outcomes.
about o2h discovery
o2h discovery has an integrated drug discovery platform operating from its state-of-the-art research centres in Ahmedabad, India, and The Mill Scitech Park, Cambridge, UK.
o2h discovery is a highly reputed service provider of mg/g scale discovery chemistry. We have partnered with a range of well known pharmaceutical and biotechnology companies from Europe, USA and Japan.
Know more
our other services
A premier contract research organisation providing integrated and biology services for collaborative research
meet our team
Sunil shah
CEO - o2h ventures and Co-founder - o2h group
Sunil shah
Sunil shah
CEO - o2h ventures and Co-founder - o2h group
Prashant Shah
CEO - o2h co-work labs and Co-founder - o2h group
Prashant Shah
Prashant Shah
CEO - o2h co-work labs and Co-founder - o2h group
Tejas Upadhyay
VP, Business Development, o2h group
Tejas Upadhyay
Claudio Dagostin
VP, Business Developement - o2h discovery
Claudio Dagostin
Claudio Dagostin
VP, Business Developement - o2h discovery
Andy morley
Chief science officer
Andy morley
Andy morley
Chief science officer
Gayathri Sadasivam
VP, Head of Biology, o2h discovery
Gayathri Sadasivam
Gayathri Sadasivam
VP, Head of Biology, o2h discovery
Hemal Soni
Head of Chemistry, o2h discovery
Hemal Soni
Hemal Soni
Head of Chemistry, o2h discovery
Dharmesh Bhatt
Analytical Head, o2h discovery
Dharmesh Bhatt
Dharmesh Bhatt
Analytical Head, o2h discovery
latest news
Read about some of the most recent developments including research collaborations at o2h discovery
subscribe to our newsletter
Please sign up to receive latest updates and insights from the o2h discovery frontline in India and UK.
